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Glioblastomas (GBMs) are the most common and
malignant primary brain tumors and are aggressively
treated with surgery, chemotherapy, and radio-
therapy. Despite this treatment, recurrence is inevi-
table and survival has improved minimally over the
last 50 years. Recent studies have suggested that
GBMs exhibit both heterogeneity and instability
of differentiation states and varying sensitivities
of these states to radiation. Here, we employed an
iterative combined theoretical and experimental
strategy that takes into account tumor cellular het-
erogeneity and dynamically acquired radioresistance
to predict the effectiveness of different radiation
schedules. Using this model, we identified two deliv-
ery schedules predicted to significantly improve effi-
cacy by taking advantageof the dynamic instability of
radioresistance. These schedules led to superior sur-
vival inmice. Our interdisciplinary approachmay also
be applicable to other human cancer types treated
with radiotherapy and, hence, may lay the foundation
for significantly increasing the effectiveness of a
mainstay of oncologic therapy.
INTRODUCTION
Patients suffering from glioblastoma (GBM), the most common
and malignant primary brain tumor, have very poor survival.
The standard of care is surgery when possible followed by
radiation (Figure 1A) and chemotherapy (Stupp et al., 2005).
This regime has seen little change over the past 50 years, as
has the overall survival for this disease. Radiation is used inadjuvant therapy globally and provides a significant increase in
the survival of GBM patients (Walker et al., 1980). Dose escala-
tion studies demonstrated that survival improvements are
observed up to an overall dose of 60 Gy (Walker et al., 1979).
Beyond this point, there are little, if any, improvements in survival
at the cost of increased toxicity (Bleehen and Stenning, 1991;
Chan et al., 2002; Morris and Kimple, 2009). Typically, the dosing
schedule is 2 Gy per day, 5 days per week, for 6 weeks. Several
alternative schedules have been attempted, such as hypofrac-
tionated dosing of 3–6 Gy per session, hyperfractionated dosing
of 1 Gy fractions two to three times per day, and accelerated
dosing using multiple 2 Gy fractions a day to shorten the overall
treatment time (Laperriere et al., 2002). None of these strategies,
however, have resulted in consistent improvements in tumor
control or survival and are thus not routinely used in the clinic.
Three recent advances provide insights into GBM biology
that may impact therapy. First is the realization that GBM falls
into several molecular subgroups that appear to be dominated
by specific signaling pathways (Brennan et al., 2009; Phillips
et al., 2006; Verhaak et al., 2010). These subgroups include
proneural GBM that is related to abnormal platelet-derived
growth factor (PDGF) signaling, classical GBM with canonical
epidermal growth factor receptor (EGFR) amplification, and
mesenchymal GBM with common loss of NF1 function. The
second advance is the development and use of genetically
engineered mouse models of GBM that provide genetically
and histologically accurate models of these molecular subtypes
of GBM (Hambardzumyan et al., 2011; Huse and Holland, 2009;
Sharpless and Depinho, 2006). The third development is a series
of work describing a subset of glioma cells that share many
characteristics with stem cells (Galli et al., 2004; Ignatova
et al., 2002; Singh et al., 2004). These cells are preferentially
resistant to radiation and temozolomide and are considered an
underlying cause of disease recurrence (Bao et al., 2006; Chen
et al., 2012; Liu et al., 2006).Cell 156, 603–616, January 30, 2014 ª2014 Elsevier Inc. 603
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Figure 1. Human and Murine Gliomas Display Similar Recurrence Patterns in Response to Radiation
(A) Representative MRIs showing human and mouse gliomas that are resolved by radiation treatment but then recur.
(B) Representative images andquantification of a radiation dose response assayed inE2f1-Lucglioma-bearing 24 hr after a given radiation dose. Error bars are SD.
(C) Schematic of the mathematical model used to describe the radiation response. The tumor is modeled as two separate cellular components: the stem-like
resistant cells (SLRCs) and the differentiated sensitive cells (DSCs). SLRCs can repopulate the tumor, and someDSCs cells, represented by g, are able to revert to
SLRCs in response to radiation.
(D) Flow-chart summarizing the workflow described in the paper.
See also Figure S1.
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The PDGF-induced mouse model of GBM accurately mimics
the 25%–30% of human GBMs in which aberrant PDGF
signaling is present (Brennan et al., 2009; Shih et al., 2004;
Verhaak et al., 2010). This model also contains a subpopulation
of tumor cells that have similarities to stem cells (Barrett et al.,
2012; Bleau et al., 2009; Charles et al., 2010). Stem-like cells
are thought to reside in the perivascular niche and are main-
tained in that state at least partly by nitric oxide (NO) that signals
through cyclic guanosine monophosphate, PKG, and NOTCH
(Calabrese et al., 2007; Charles et al., 2010; Eyler et al., 2011).
Within as little as 2 hr, NO can induce tumor cells to acquire a
stem-like phenotype resulting in enhanced neurosphere and
tumor formation upon transplantation (Charles et al., 2010).
Other niche factors, such as hypoxic conditions, have also
been shown to induce stemness (Heddleston et al., 2009;
Li et al., 2009). Additionally, recent work has demonstrated
that there aremultiple tumorigenic cell types within a given tumor
and that terminally differentiated astrocytes and neurons can
dedifferentiate under oncogenic stress (Chen et al., 2010; Fried-
mann-Morvinski et al., 2012). These observations suggest that
GBMs possess a dynamic heterogeneity of differentiation states
that may allow them to rapidly and dynamically acquire a more
resistant phenotype.
We hypothesized that mathematical modeling of this dynamic
plasticity could be used to enhance radiation therapy. In the
past few decades, the vast majority of mathematical modeling
of the effects of radiation on cells has been based on the linear
quadratic model. This model is widely accepted in the radiation
literature due to its close agreement with experimental results for
almost all radiation values of clinical interest (Hall and Giaccia,
2012). Several previous studies have specifically investigated
the impact of radiotherapy on glioblastoma (Dionysiou et al.,
2004; Harpold et al., 2007; Rockne et al., 2009; Stamatakos
et al., 2006). These studies range from purely computational
experiments to models fitting clinical data and have been utilized
in predicting the outcomes of accelerated hyperfractionated
schedules. Other recent work has successfully utilized mathe-
matical modeling of cellular in vitro or rat-based in vivo systems
to describe glioma behavior (Gao et al., 2013; Massey et al.,
2012). Despite the multitude of work that has been done
on optimal fractionation schedules, there has been very little
success against aggressive gliomas in the clinic (Gupta and
Dinshaw, 2005).
Here, we aimed to model a dynamic radiation response with
the goal of identifying optimal schedules capable of improving
radiation efficacy in a mouse model of PDGF-driven glioma.
Our model considers two separate populations of cells: the
largely radioresistant stem-like glioma cells and the radiosen-
sitive differentiated glioma cells. We hypothesized that, after
exposure to radiation, a fraction of the radiosensitive cells could
rapidly revert to the radioresistant state. The inclusion of this
dynamic hierarchical population structure and its plasticity
induced by exposure to ionizing radiation is a key feature
of our framework. Based on this model, we described an
optimized schedule that was predicted to prolong survival.
Crucially, when tested in a clinically relevant glioma mouse
model, this schedule markedly improved survival compared to
a standard schedule. The fidelity of the model was improvedby adding nonlinear temporal constraints to the acquisition of
radioresistant properties based on the time since the previous
radiation treatment. This second iteration of the model was
able to generate a second optimized schedule that also
improved survival in glioma-bearing mice. The mathematical
model identifies the fraction of cells capable of acquiring radio-
resistance and the temporal constraints under which this pro-
cess occurs as sensitive parameters for predicting radiation
response. Specifically, our model predicts that if tumors were
unable to rapidly acquire radioresistance, there would be no
benefit to any of the optimum schedules. Our data support
the functional importance of dynamic radioresistance to therapy
and suggests that, at least in PDGF-driven glioma, the standard
radiation schedule used may not be optimal. These findings
may have broad implications for improving radiation therapy
and provide a framework for future optimization of cytotoxic
treatment delivery.
RESULTS
Initial Characterization of Radiation Dosing Using an
Animal Model for PDGF-Driven GBM
We first performed a dose-response study to determine
the effectiveness of various single-fraction doses of radiation
(Figure 1B). We generated PDGF-B-induced tumors in Nestin-
tv-a;E2f1-Luc mice using the replication-competent ASLV
long-terminal repeat (LTR) with a splice acceptor (RCAS)/t-va
mouse-model system (Uhrbom et al., 2004). These mice ex-
press firefly luciferase driven by the E2f1 promoter (E2f1-Luc),
allowing for a noninvasive readout of cellular proliferation. This
model is similar to human gliomas, in that glioma-bearing
mice transiently respond to radiation treatment but ultimately
succumb to disease recurrence (Figure 1A). We irradiated
glioma-bearing mice with a variety of single doses: 2 Gy
(approximately the daily dose used in humans), 4 Gy, 10 Gy,
and 15 Gy. Twenty-four hours after irradiation, we found a
progressive decrease in E2F1-drive bioluminescence activity
with increasing radiation dose that appeared to plateau around
10 Gy (Figure 1B). For this reason, we chose a 10 Gy dose for
further investigations.
Mathematical Modeling of GBM Cell Dynamics Predicts
Treatment Response
We designed a mathematical model of GBM cell dynamics in
response to radiation therapy. The model considers two distinct
subpopulations of cells: stem-like/resistant cells (SLRCs) and
differentiated/sensitive cells (DSCs) (Figure 1C). SLRCs repro-
duce symmetrically at rate rs to give rise to two SLRCs and asym-
metrically at rate as to produce a SLRC and a DSC. Initially, the
ratio of DSCs to SLRCs is given by R. Our model incorporates
a bidirectional flow of cells between the SLRC and DSC states.
In addition to SLRCs converting to a differentiated sensitive
state, our model assumes that a fraction of DSCs may be
capable of reverting to become SLRCs after exposure to ionizing
radiation (Bleau et al., 2009; Charles et al., 2010; Chen et al.,
2012; Li et al., 2009; Pistollato et al., 2010). The rate at which
DSCs revert to a stem-like state is given by n, and the fraction
of DSCs that can revert is given by g.Cell 156, 603–616, January 30, 2014 ª2014 Elsevier Inc. 605
SLRCs are relatively radioresistant, whereas DSCs respond
to radiation therapy via cell-cycle arrest, mitotic cell death, and
apoptosis (Bao et al., 2006; Chen et al., 2012; Hambardzumyan
et al., 2008). We modeled the cell population response to
radiotherapy using the linear quadratic model, which is widely
accepted in the radiation literature due to its close agreement
with experimental results (Dale, 1985; Fowler, 2010). The basic
linear quadratic model states that the fraction of cells that
survives a radiation dose of d Gy is given by exp[ad  bd2].
The parameters a and b are specific to the type of tissue that is
being irradiated; the parameter a represents cell killing resulting
from a single radiation track causing damage to a specific chro-
mosomal locus, whereas b represents cell killing via two tracks
of radiation causing damage at the same locus. Within our math-
ematical framework, the parameters as and bs characterize the
response of SLRCs to radiation, whereas the parameters ad
and bd denote the response of DSCs. In order to simplify the
model, we considered the increased radiosensitivity of DSCs to
be expressed in relation to the SLRC radioresistance, repre-
sented by the parameter r. In particular, we assumed that 0%
r% 1, as = r ad, and bs = r bd. Therefore, the sensitivity of SLRCs
to radiation can be characterized by a single parameter, r.
Our model also included radiation-induced cell-cycle arrest
and attempted DNA-damage repair (Bao et al., 2006). In the
context of our model, this arrest lasts for a minimum of Ls and
Ld time units after radiation exposure in SLRCs and DSCs,
respectively, and the rates at which these cells exit cell-cycle
arrest are given by ls and ld. Further, newly converted DSCs
take a minimum of Md units of time to begin reproducing again,
and this event occurs at rate hd.
Using this notation, we then formulated a mathematical model
to describe the numbers of SLRCs and DSCs in response to
radiation. At the time of diagnosis of the disease, there are NS0
SLRCs and Nd0 DSCs. When these cells are exposed to the
first dose of d Gy of radiation, there occurs a change in their
numbers according to the linear quadratic model, producing
NS0 exp[asd  bsd2] SLRCs and Nd0 exp[add  bdd2] DSCs.
Additionally, there are g Nd0 exp[add  bdd2] DSCs that are
capable of reverting to the SLRC state. Using this description,
we can then calculate the number of cells present at time t after
exposure of the cell population to a dose of radiation. The
number of DSCs is given by the number of DSCs that survived
radiation and do not have the potential to revert to SLRCs plus
any new growth and conversion from SLRCs since treatment;
in addition, there are DSCs in the process of reversion. Similarly,
the number of SLRCs is given by the population of cells that sur-
vived the dose of radiation plus any growth and reversion that
has occurred since then:
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where we use the notation x+ = x, xR 0, and x+ = 0, x < 0. Further,
note that, for the sake of readability, we have assumed that the
rates ls, ld, and hd are sufficiently large so they can be ignored;
for the optimization described below, however, these termswere
included (values listed in Table 1). For the full model without this
assumption, see Equations 7 and 8 in the Supplemental Informa-
tion available online.
We can use the analytic description above to predict the
response of the tumor to any course of radiation therapy.
Determination of an Optimal Radiation Schedule
To evaluate the response to a given radiation schedule in the
context of our mathematical model, we considered the number
of tumor cells present 2 weeks after treatment conclusion as
an endpoint. To implement the optimization algorithm, an initial
set of parameter values was derived from preliminary data (Fig-
ure 1B), previous studies (Galba´n et al., 2012; Hambardzumyan
et al., 2009; Pitter et al., 2011), or estimates (Table 1; Supple-
mental Information). We then predicted the survival outcomes
for 10 Gy either administered as a single dose or in a clinically
standard treatment (5 days of 2 Gy), finding that a standard
fractionation schedule would perform significantly better than a
single dose (Figures 2A and 2D).
We then aimed to identify an optimal fractionation schedule,
with the goal of finding those schedules that minimized the
number of tumor cells 2 weeks after the treatment conclusion.
Mathematically identifying the global optimal schedule was not
computationally feasible due to the complexity of our model,
as well as the uncertainty of some of the parameters. Because
of this, we utilized simulated annealing, a Monte-Carlo-based
method (Kirkpatrick et al., 1983; Van Laarhoven and Aarts,
1987), to identify the best treatment strategies (see Supple-
mental Information; Table 2).
A clinically motivated constraint set for our schedules is pre-
sented in the Supplemental Information. With this constraint
set and using our initial set of parameters (Table 1), we identified
an optimal schedule, ‘‘optimum-1,’’ that was predicted to do
significantly better than standard treatment. We also created a
control schedule by generating a scrambled sequence with a
similarly clustered dosing scheme that was predicted to not
perform significantly better than standard treatment (Figures
2A and 2D; Table 2).
AnOptimizedRadiation Schedule Significantly Improves
Survival in a Mouse Model of PDGF-Driven Glioma
We then returned to the RCAS/t-va mouse system to test the
model’s predictions in a survival assay. We performed survival
experiments using PDGF-B-driven gliomas in Nestin-tv-a;
Ink4a/Arf/ mice. The genetic background of these mice is
similar to human PDGF-driven tumors (Verhaak et al., 2010).
As mice developed symptoms of glioma, such as lethargy,
weight loss, seizures, etc., they were randomized into either
the mock-treated group or one of the various 10 Gy radiation
treatment groups, which consisted of a single dose, standard
fractionation, optimum-1, and a scramble control (Table 2). The
Table 1. Description and Values of the Mathematical Model Parameters
Biological Process Symbol Original Parameter Second Iteration Final Iteration
Per Gy production of lethal DNA lesions from
single radiation track in DSC and SLRC
ad/as 0.0987/0.0395 0.0987/0.0429 0.0987/0.00987
Per Gy2 production of lethal DNA lesions
from two radiation tracks in DSC and SLRC
bd/bs 1.14 3 10
7/4.58 3 108 1.14 3 107/4.96 3 108 1.14 3 107/1.14 3 108
Rate at which newly converted DSC lead to
clonal expansion (hr)
hd 0.5 0.092 0.054
Minimum time for newly converted DSC to
begin clonal expansion (hr)
Md 24 313.256 366.3
Minimum time DSC and SLRC are in
quiescence (hr)
Ld/Ls 24/36 461.46/464.99 193.32/477.02
Rate at which DSC and SLRC exit quiescence ld/ls 0.5/0.35 .011/.0001 .1/.0328
Proliferation rate of DSC and SLRC after
exiting quiescence
rd/rs .0088/.0001 .0057/.0001 .0038/.0008
Initial ratio of DSC to SLRC R 20 20 20
Rate at which SLRC convert to DSC as 0.0001 0.0001 0.0019
Rate of reversion of DSC to SLRC n 1.15 3.64 0.45
Fraction of DSC capable of reverting to SLRC g 0.15 0.353 0.4
Time to peak reversion after irradiation m - 3.5 3.25
Width of window of reversion s2 - 2.5548 1.46endpoint of survival was defined as the time point at which the
animal had to be sacrificed because of excessive tumor burden:
greater than 10%weight loss, lethargy, or seizure. Mock-treated
mice quickly succumbed to their disease, with a median overall
survival of 5 days after the onset of symptoms (Figure 2B).
Animals in the single-dose and the clinical-standard groups
had respective median survivals of 28.5 and 33 days after
the onset of symptoms, which was significantly longer than the
mock-treated group (p < 0.0001; Figure 2B). Although the
median survival of the single dose-treated animals was shorter
than the standard treatment group, there was no significant dif-
ference between treatments (hazard ratio [HR] [95% confidence
interval (CI)] = 1.619 [0.8450–3.932]; p value = 0.1742; Figures 2D
and 2E).
We also analyzed two different mathematically predicted
schedules: optimum-1 and the scrambled control sequence
(Figures 2A and 2D; Table 2). The median survival of mice
treated with the scrambled control schedule was 30 days (Fig-
ure 2B), which was not significantly different from the standard
schedule (HR [95% CI] = 1.613 [0.7453–4.863]; p value =
0.2346; Figures 2D and 2E). Mice treated with optimum-1 had
a median survival of 50 days (Figure 2B), which was signifi-
cantly longer than the clinical standard schedule (Figures 2D
and 2E; HR [95% CI] = 0.3015 [0.04708–0.3760]; p value =
0.001). Due to the increase in median survival observed with
the optimized schedule, we next compared the optimized
schedule to 2 weeks of clinical standard therapy; in the latter,
mice were treated with 20 Gy, delivered in ten fractions
given over 12 days, with a 2-day weekend break. The 20 Gy
treatment group had a median survival of 53 days (Figure 2B),
which was significantly greater than the 10 Gy clinical standard
(Figures 2D and 2E; HR [95% CI] = 0.2084 [0.01295–0.1319];
p < 0.0001), but not significantly different from optimum-1(Figure 2E, HR [95% CI] = 1.429 [0.6230–3.698]; p value =
0.3907).
Mathematical Modeling of Other Clinically Relevant
Fractionation Schedules Leads to Iterative Updating of
the Model
We then set out to investigate other fractionation schedules that
have been clinically tested in GBM. Hyperfractionation sched-
ules consist of a large number of smaller-dose treatments in
an attempt to minimize damage to surrounding normal tissue,
but according to clinical trials, this approach has not improved
overall survival (Coughlin et al., 2000; Laperriere et al., 2002).
Hypofractionation schedules involve a larger fraction size with
fewer treatments, resulting in a shorter overall treatment time
that again yields similar survival to conventional therapy (Laper-
riere et al., 2002). Surprisingly, our initial model predicted that
both hypo- and hyperfractionated schedules would perform
significantly differently than standard therapy: the hypofractio-
nated schedule was predicted to be similar to a single dose
of 10 Gy, whereas a standard hyperfractionated schedule was
predicted to perform as well as or slightly better than opti-
mum-1 (Figures 3A and 3G).
We tested this prediction for both schedules by overall survival
in mice. Mice were randomized as described above into either
a hyperfractionated group or hypofractionated group and
compared to standard therapy (Table 2). Mice treated with these
schedules had a median survival of 37.5 days and 36 days,
respectively (Figure 3B). Similar to results observed in human
clinical trials, neither of these schedules was significantly
different from the clinical standard schedule (Figure 3D; HRhyper
[95%CI] = 0.5237 [0.1708–1.167]; p value = 0.1383; HRhypo [95%
CI] = 0.3427 [0.1123–1.046]; p value = 0.0599). These results,
and the hyperfractionated schedule in particular, highlighted aCell 156, 603–616, January 30, 2014 ª2014 Elsevier Inc. 607
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Figure 2. Mathematical Modeling of the Radiation Response Improves Survival in a Mouse Model of Proneural Glioma
(A) Original model-predicted tumor response and growth following standard, single-dose, optimum-1, and scramble control radiation treatment schedules.
Model parameters are listed under ‘‘Original Parameters’’ in Table 1.
(B) Kaplan-Meier survival plot of various radiation schedules. IR, ionizing radiation.
(C) Schematic depicting the various schedules tested. The arrow position represents the time of dose during the 8am–5pm treatment window. The size of the
arrow correlates with the size of the dose.
(D) Table summarizing number of mice treated, the performance relative to standard therapy, and the original model-predicted performance of each group. ns,
not significant.
(E) Hazard ratios of the various radiation schedules, compared to the standard radiation schedule. Error bars represent the 95% confidence interval (CI) of the
hazard ratio (HR).
See also Figure S2.weakness in our model that we addressed with a second itera-
tion of the model.
Time-Dependent Acquisition of Radioresistance
Improves the Mathematical Model
To address the inaccurate predictions of the original model,
we iteratively updated our model such that the fraction of
cells rapidly acquiring resistance, g, now depends on the time
elapsed since the previous dose of radiation. Whereas the initial
model treated g as a time-independent constant following radi-
ation, the updated model stipulates that g varies over time and
that there is a time where a maximum number of cells are prone
to reversion in response to subsequent exposure to ionizing
radiation. The updated model thus describes the acquisition
of resistance with two additional time-dependent parameters:
the time of maximal reversion after radiation, m, and the width
of the window during which reversion can occur after radiation,608 Cell 156, 603–616, January 30, 2014 ª2014 Elsevier Inc.s2. The model stipulates that, after the first dose of radiation,
g0 cells are capable of reversion; for a later dose given t hr after
the previous dose of radiation, the fraction of cells capable
of reversion is given by gðtÞ=goeðtmÞ
2=s2 . Other than these
additional parameters added to further describe g, the updated
model is the same as the original model.
To investigate this time-dependent model, we first tested
its predictions against volumetric time series data of mice after
treatment with 2 weeks of standard therapy (Figure 3E). This
comparison allowed us to identify parameter values capable
of recapitulating the time-series data. Based on these model
parameters, we found a closer concordance between predicted
mouse survival times and observed experimental survival times
of the optimum-1, hyperfractionated, hypofractionated, and
standard schedules (Figures 3F and 3G). In addition to more
accurately predicting the survival response, the model also
makes significantly different predictions with regard to the
Table 2. Description of the Tested Radiation Schedules
Schedule Day 1 Day 2 Day 3 Day 4 Day 5
Standard 2 Gy 2 Gy 2 Gy 2 Gy 2 Gy
Single dose 10 Gy – – – –
Optimum-1 1 Gy 1 Gy 1 Gy 1 Gy 1 Gy
8am 5pm 3pm 5pm 3pm
2pm 5pm 4pm
5pm 5pm
Scramble control 1 Gy 1 Gy 1 Gy 1 Gy –
10am 4pm 2pm 1pm
11am 3pm 2pm
12pm 4pm 3pm
Hypofractionated 5 Gy – – – 5 Gy
Hyperfractionated 1 Gy 1 Gy 1 Gy 1 Gy 1 Gy
9am 9am 9am 9am 9am
3pm 3pm 3pm 3pm 3pm
Optimum-2 3Gy 1 Gy – 1 Gy 1 Gy
8am 4pm 9am 9am
1pm 1pm
5pm 5pmenrichment of the SLRC population after radiation. Both models
similarly predict that 1 day after the last dose, optimum-1 will
lead to a larger number of SLRCs relative to standard therapy.
However, the models offer differing predictions for the hyper-
fractionated schedule. The original model predicts that the
hyperfractionated schedule maximally enriches the SLRC
population among all schedules tested (Figure 4A), whereas
the time-dependent model predicts that optimum-1 enriches
the SLRC population to a greater extent than the hyperfractio-
nated schedule (Figure 4B).
To test the effects of various schedules on the enrichment of
SLRCs, we then treated mice with the standard, hyperfractio-
nated, and optimum-1 schedules. Glioma tissue was harvested
for side-population (SP) analysis on the sixth day, i.e., 1 day after
the last dose of radiation. Stem-like cells are frequently identified
from a variety of normal and malignant tissues by flow cytometry
as the SP based their ability to efflux Hoechst dye via the ABC
transporter, ABCG2 (Greve et al., 2012). Previous work has
demonstrated that, in PDGF-driven murine gliomas, SP cells
are enriched for canonical cancer stem cell properties, such as
stem-marker expression, enhanced tumor-sphere formation,
and enhanced tumorigenicity (Bleau et al., 2009). We generated
tumors using a previously described RCAS vector that ex-
presses both PDGF-B and enhanced GFP, which results in gli-
omas with GFP-positive tumor cells (Fomchenko et al., 2011).
This system allowed us to limit the SP analysis to bona fide tumor
cells (Figure 4C). We observed that tumors treated with the opti-
mized schedule have a 3.55-fold enrichment when compared to
standard therapy (p value = 0.0265; Figure 4D). However, as pre-
dicted by the time-dependent mathematical model, the hyper-
fractionated therapy was not able to statistically significantly
enrich the SP when compared to standard treatment (1.145-
fold enrichment; p value = 0.5944; Figure 4D).To further validate the time-dependent model, we used it to
derive an optimized schedule, ‘‘optimum-2’’ (Table 2). As with
optimum-1, optimum-2 was predicted to lead to an enriched
number of SLRCs 1 day after the last dose of radiation compared
to standard treatment (Figure 4B). Tumors treated with the
optimum-2 schedule had a 2.6-fold enrichment when compared
to standard therapy (p value = 0.0210; Figure 4D). Although
optimum-2 was predicted to enrich the SLRCs further than
optimum-1, we saw no significant difference in the SP between
the two groups (p value = 0.3805). We also tested the opti-
mum-2 schedule using overall survival in mice and observed a
significant improvement in survival compared to standard
treatment (hazard HR [95% CI] 0.2720 [0.04074–0.2967] ratio;
p value < 0.0001; Figure 4E). Optimum-2 was also predicted to
have longer survival than optimum-1 (Figure S3). The median
survival of the optimum-2 group was longer than that of the
optimum-1 group; this difference, however, did not reach statis-
tical significance (Figure 4F; HR [95% CI] = 0.8788 [0.4572–
1.689], p value = 0.1768).
To further improve the predictive accuracy of the model, we
performed a final iteration by reparameterizing the model using
the experimental survival data (Figures 5A and 5B). Performing
this calculation led to a further confirmation that the time depen-
dence of gwas essential to themodel: fitting the time-dependent
model to the survival data led to a smaller minimal mean square
error as compared to the original model. The time-dependent
model was able to fit the observed data to within an error of
5.2 days, in contrast to the original model, which could only fit
the data to an error of 16.32 days. Thus, including time-depen-
dent dedifferentiation increases the model’s ability to match
the survival data. We therefore concluded that the time-depen-
dent form of g is necessary to accurately explain the observed
survival data and it is likely that any cell reversion due to ionizing
radiation occurs in a time-dependent fashion.
Lastly, we created a simplified version of the model that
was more suitable for analysis and interpretation. The simplified
model predictions for the tumor cell populations prior to dose
i+1 (assuming t hours between doses i and i+1, and t0 hours
between doses i1 and i) are given by
Ndi + 1 = ð1 gðt0ÞÞerdðtLdÞ +Ndi eaddi
Nsi + 1 =N
s
i e
asdi +gðt0ÞNdi eaddi
According to this simplified form of the model, the optimized
therapies optimum-1 and optimum-2 increase survival by con-
verting cells from the fast-growing radiosensitive population to
the slow-growing radioresistant population. Notably, sensitivity
analysis of the simplified model identifies the parameters that
describe reversion as novel sensitivity parameters (Figure 5C;
Supplemental Information).
Finally, as a thought experiment, we considered this model in a
settingwhere there is no reversion (g0 = 0) and therefore no ability
to rapidly acquire radioresistance. Under these conditions, the
model reduces to the standard linear quadratic model, which
highlights two important observations. First, in this scenario, all
fractionation schedules would result in the same ratio of stem-
like to differentiated cells (Figure 5D). This finding is in clear
contradiction to the observations of our SP analysis (Figure 4D).Cell 156, 603–616, January 30, 2014 ª2014 Elsevier Inc. 609
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Figure 3. Comparison of Two Models: Incorporating Dedifferentiation Time Dependence Improves Fidelity
(A) Predicted tumor growth in response to standard, hypofractionated, hyperfractionated, and optimum-1 radiation treatment schedules. These curves are based
on the original model; parameters are listed under Original Parameters in Table 1.
(B) Kaplan-Meier survival plot of hypo- and hyperfractionated radiation schedules. Mock-treated and standard survival are the same curves as Figure 2 and are
shown for comparison.
(C) Schematic depicting the hyper- and hypofractionated schedules tested. The arrow position represents the time of dose during the 8am–5pm treatment
window. The size of the arrow correlates with the size of the dose.
(D) Hazard ratios of the hypo- and hyperfractionated radiation schedules, compared to the standard radiation schedule. Error bars represent the 95%CI of theHR.
(E) Reparameterization of the time-dependent model based on volumetric MRI studies of mouse gliomas treated with 2 weeks of the standard schedule.
(F) Time-dependent model-predicted tumor growth in response to the various treatment schedules. Model parameters are listed under ‘‘Second Iteration’’ in
Table 1.
(G) Table summarizing number of mice treated, the performance relative to standard therapy, and the predicted performance of the original and time-dependent
model for each treatment group.
See also Figure S3.Second, if there was no reversion, the model would predict that
all fractionation schedules result in the same survival (Figure 5E),
which is also contradicted by the observations from mouse
survival experiments (Figures 2B and 4E). Taken together, these
observations provide significant evidence for the fact that
ionizing radiation encourages rapid reversion of a subset of
glioma cells to a radioresistant stem-like state.
In sum, our iterative mathematical modeling approach,
informed and validated by mouse modeling, allowed us to deter-
minenot only a radiationdelivery schedule that prolongedsurvival
in mice, but also to identify parameters of the biological pro-
cesses guiding cellular behavior in gliomas that are responsible
for radioresistance. This validated mathematical model can be
used, in futurework, to investigate the effectiveness of alternative
schedules and test their effects on GBM cell populations.610 Cell 156, 603–616, January 30, 2014 ª2014 Elsevier Inc.DISCUSSION
Standard radiation delivery schemes are based on decades-old
data that mostly predate recent findings on cancer stem cells. In
GBM patients, many different radiation schedules have been
tried in the clinic based on classic radiobiological data, but
thus far all have had roughly the same effectiveness. Here, we
adopted a combined experimental and theoretical approach
with the goal of identifying treatment schedules that would
lead to better survival in animal models of the disease by
accounting for dynamic transitions of cells between relatively
radiosensitive and radioresistant pools. Our approach was
based on the assumption that the tumor has a kinetic response
to radiation causing some of the surviving cells to acquire resis-
tance by adopting amore stem-like quiescent state over amatter
of hours. Based on this approach, we successfully identified two
treatment schedules that significantly extended survival in
glioma-bearing mice, whereas a control schedule failed to do
so, as predicted. The fact that optimized schedules clearly out-
performed other schedules suggests that the response to radia-
tion is dynamic and that the schedule of a given total dose of
radiation can affect its ultimate efficacy.
Although the mathematical model presented here offers
complexity, it does not include several potentially important bio-
logical factors, such as the immune system, stromal-tumor inter-
actions, nutrient gradients, and others. For example, the work by
Stamatakos et al. (2006) developed a sophisticated four-dimen-
sional model for the response of high-grade gliomas to ionizing
radiation. Based on their computational model, the authors are
able to discuss the effects of cell-cycle time, reoxygenation
times, and cell density on tumor response to therapy. Whereas
these factors are important, using a simplified model focusing
on a single factor, such as dynamic radioresistance, is a powerful
way to isolate and better study that phenomenon. Additionally, it
has previously been shown that working with a simplified model
allows for a more thorough exploration of the mathematics
behind the specific parameter, which often uncovers nonobvious
predictions (Michor et al., 2005; Norton, 1988). Lastly, simplified
models are amenable to more complex mathematical analysis,
such as optimization of treatment schedules.
Glioma stem cells are functionally defined by their capacity to
self-renew and to generate heterogeneous tumors upon trans-
plantation (Vescovi et al., 2006). As stem-like cells are more ther-
apeutically resistant and ultimately give rise to recurrent disease,
it is commonly believed that decreasing the stem-like population
will increase overall survival (Cheng et al., 2010; Scopelliti et al.,
2009). However, our model predicts an improved overall survival
for fractionation schedules that enrich the SLRC population. The
side population, which is enriched for quiescent stemcells (Bleau
et al., 2009; Deleyrolle et al., 2011; Harris et al., 2008), was
elevated in the two optimized schedules that increased overall
survival. However, the success of our model is driven by these
cells acquiring a quiescent state and slower proliferation rate
and therefore is not dependent on a complete dedifferentiation.
Further characterization of the ability of radiation to induce other
stem-like properties remains an exciting area for future studies.
While eradicating all glioma cells, including the stem-like popu-
lation, is essential for ultimately curing the disease, our model de-
scribes a phenomenonwhereby utilizing alternatively fractionated
schedules can increase the SLRC population and still result in a
slower-growing residual tumor and prolonged time to recurrence.
In this regard, our model joins a growing body of evidence sug-
gesting that the relationship between cells with stem-like char-
acter and clinical outcomes might not be as straightforward as
previously thought. A recent theoretical paper modeling tumor
growth kinetics argues that,whereascancer stemcells areneces-
sary for tumor growth, thekinetics of growtharebest describedby
the nonstem compartment (Morton et al., 2011). Additionally, a
recent human GBM study compared the percentage of CD133+
glioma stem cells in patient-matched primary and recurrent sam-
ples (Pallini et al., 2011). Patients whose gliomas contained an
increased percentage of CD133+ at recurrence demonstrated a
significantly longer survival than those with decreased CD133+cells at recurrence. These studies support our finding that a rela-
tive enrichment in the resistant stem-like populationmight prolong
survival by increasing the time to recurrence.
Translating Optimized Schedules to Human Patients
There are some clear hurdles and open questions in regards to
translating our findings from themouse to theclinic.Onemeasure
of predicted toxicity and lethality of different fractionation sched-
ules is given by the biologically effective dose (BED) (Fowler,
2010; Hall and Giaccia, 2012). This measure is frequently used
to compare the effectiveness and toxicity of different schedules.
It is difficult to use BED to compare the optimized schedules
testedhere, as the spacing of our doses is inconsistent. However,
if we use the common assumption that doses separated bymore
than 6 hr are independent, then the optimum-1 schedule had one
of the lowest BED values of all schedules tested. Because of this,
it might even be possible to increase the dosage levels while
keeping the toxicity of the schedule at or below the level of the
standard therapy. An important avenue for extending these re-
sults to the clinical setting will be to consider optimizing fraction-
ation schedules while stipulating that the schedule has an equal
or lower BED than that of standard therapy.
Note also that this treatment approach enriches a slow-
growing glioma stem cell (GSC) population and therefore would
not be curative. However, previous studies have shown that can-
cer stem cells are dependent on the NOTCH signaling pathway
(Androutsellis-Theotokis et al., 2006; Charles et al., 2010; Eyler
et al., 2011), and further studies have shown depletion and ther-
apeutic sensitization of GSCs when treated with gamma-secre-
tase inhibitors (Gilbert et al., 2010; Hovinga et al., 2010; Wang
et al., 2010). Future studies that combine optimized radiation
with therapeutics that specifically target GSCs, via NOTCH or
other pathways, might further improve outcomes.
GBM is by definition a heterogeneous disease, and it is unclear
how robust an optimized schedule developed for proneural
glioma would perform across the various other GBM subtypes.
The mouse model used in these studies is driven by PDGF
signaling, which is characteristic of approximately 25%–30%
of human GBMs. Of note, this mouse model might not reflect
the biology of other commonly altered signaling pathways,
such as EGFR amplification or NF1 loss, and further studies
are needed to determine if the optimization will extend to those
tumors. Additionally, even tumors with similar molecular under-
pinnings are likely to exhibit variability in the parameters used
to optimize radiation delivery, such as proliferation rate and
the fraction of cells capable of rapidly acquiring resistance.
This observation brings up the possibility theremay be no univer-
sal optimum schedule but rather multiple schedules where opti-
mization for a given patient is dependent on detailed pathologic
analysis of each resected tumor.
Additionally, the parameter values we used were determined
iteratively based on the mouse model, and it is probable that
the schedules presented here will not translate precisely to
human tumors. Our investigation was performed for 1 week of
therapy delivering a total of 10 Gy of radiation. Human patients
receive 60 Gy of radiation over 6 weeks, and optimizing that
schedule might not simply be six cycles of the 1 week optimized
schedules. Nevertheless, our findings suggest that the gliomasCell 156, 603–616, January 30, 2014 ª2014 Elsevier Inc. 611
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Figure 4. Optimized Radiation Schedules Enrich the Glioma Stem Cell Population
(A and B) Graph showing predicted SLRC/DSC ratio for hyperfractionated, optimimum-1, and optimum-2 schedules, using the original model (A) or the time-
dependent model (B). All values are normalized to predictions for standard therapy. Parameters in (A) and (B) are, respectively, from the Original Parameters and
Second Iteration in Table 1.
(C) Representative gating strategy for eGFP+ tumor cell side-population (SP) analysis. The upper panel depicts the gate used to identify GFP-positive cells, based
on a GFP-negative sample shown in the insert. The lower panel depicts the gate used to identify the SP, based on a Fumitremorgin C-verapamil-treated control
shown in the insert.
(legend continued on next page)
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Figure 5. Growth Rate and Dynamic Dedifferentiation Are the Most Influential Parameters in Modeling Radiation Response
(A) Survival-fit, model-predicted tumor growth in response to various radiation treatment schedules. These predictions are from the time-dependent model
reparameterized to fit the mouse survival data with the parameters under ‘‘Final Iteration’’ in Table 1.
(B) Table summarizing the number of mice treated, the performance relative to standard therapy, and the predicted performance survival data reparameterized
time-dependent model for each treatment group.
(C) Sensitivity analysis of the model’s parameters, ranked from most to least sensitive, as determined by the sensitivity analysis (Supplemental Information).
(D) Predictions of the SLRC/DSC ratio while varying the fraction of cells capable of reversion (go).
(E) Sensitivity plot showing the relative efficacy of several schedules while varying the fraction of cells capable of reversion (go). An explanation of how we found
the parameters for (E) can be found in Section 5 of the Supplemental Information.
See also Figure S4.respond dynamically and that the response follows kinetics with
a timescale of hours, not weeks. It is therefore imperative to
include such considerations into a theoretical framework in order
to determine optimum radiation administration schedules for
human patients.
Finally, our work studied radiation in isolation, whereas inman,
radiation is usually administered after neurosurgical resection
and with temozolomide. These treatment modalities need to be
incorporated into models aimed at identifying dosing strategies
for human patients. Nonetheless, our studies suggest that(D) Representative images and quantification of SP analysis 24 hr after the conclus
For quantification, all values are normalized to the average SP of the standard sc
(E) Kaplan-Meier analysis comparing standard, optimum-1, and optimum-2 sched
2 and 3.
(F) Hazard ratios of the optimum-1 and optimum-2, compared to standard radia
(G) Schematic briefly describing the optimum-1 and optimum-2 schedules. The
window. The size of the arrow correlates with the size of the dose.modeling glioma response to radiation as a dynamic heteroge-
neous process can predict a treatment schedule that improves
overall survival. It also suggests that the schedule that patients
are currently receiving may not be optimal.EXPERIMENTAL PROCEDURES
Generation of Tumors Using RCAS/TVA
All of the animal experiments were conducted using protocols approved by the
Institutional Animal Care and Use Committees of Memorial Sloan-Ketteringion of the standard, hyperfractionated, optimum-1, and optimum-2 schedules.
hedule. Error bars represent the SD.
ules. Thesemice represent an entirely independent cohort frommice in Figures
tion. Error bars represent the 95% CI of the HR.
arrow position represents the time of dose during the 8am–5pm treatment
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Cancer Center, protocol 00-11-189. Tumors were generated as previously
described by injecting RCAS-transfected DF1 cells into n-tvamice (Hambard-
zumyan et al., 2009). Mice were monitored carefully, and treatment began
when they displayed neurological symptoms, such as lethargy or head tilt
due to tumor burden, at which point they were irradiated for either biolumines-
cence (BLI) or survival assays. For BLI, mice were analyzed 24 hr after irradi-
ation. For survival, mice were monitored until recurrence of symptoms. The
various radiation schedules are described in Table 2; further details on mouse
work can be found in the Supplemental Information online.
MRI Reconstruction and Analysis
Please see the Supplemental Information online.
SP Analysis
Hoechst 33342 staining was performed as previously reported (Bleau et al.,
2009). Briefly, glioma-bearing mice were treated with standard, hyperfractio-
nated, optimum-1, or optimum-2 schedules. Twenty-four hours after the last
treatment, mice were euthanized and tissue was harvested for SP analysis.
Bona fide tumor cells were identified based on eGFP+ expression, SP was
based on Hoescht dye exclusion, and the data were analyzed by FlowJo.
Further details on the SP analysis can be found in the Supplemental Informa-
tion online.
Statistics
Please see the Supplemental Information online.
Mathematical Modeling
Please see the Supplemental Information online.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and three tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2013.12.029.
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